Drug
HS 10561
HS 10561: highest development phase Phase 1/2, developed by Hansoh Pharmaceutical. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Hansoh Pharmaceutical
Trials
| Drug | Phase | Indication |
|---|---|---|
| HS-10561 NCT06864507 | Phase 1/2 | Chronic Spontaneous Urticaria |
Latest
No recent events.
Follow HS 10561 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.